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INTRODUCTION
Gender differences, represented in
large measure by the differential effects of
sex-specific hormones, exist in a variety
of cardiovascular,(1–4) cardiopulmonary,
(5,6) neurodegenerative, (7–9) endocrine
(10) and metabolic bone diseases such as
osteoporosis (11–13). Indeed, the role of
sex steroids in cardiovascular disease has
been studied extensively (14–27). Clini-
cally, female patients show relative car-
diac protection from acute infarctions and
better outcome following myocardial in-
farction compared with males (21). Such
gender dimorphisms may be due to the
beneficial effects of estrogens or to the
absence of the deleterious effects of an-
drogens (28,29). Differences in estrogen
receptor (ER) signaling also may play a
significant role in outcome following
cardiovascular diseases (21,30–32). In ad-
dition, gender differences in proinflam-
matory signaling and immune responses
have been described (33,34). Elegant
work by Chaudry (4) and other investiga-
tors demonstrate that alteration of im-
mune function by sex steroids can lead
to therapeutic interventions and im-
proved outcomes. A better understanding
of sex hormone regulation from a cell bi-
ology perspective will be critical therefore
in improving patient outcomes.
Stem cell transplantation has revolu-
tionized the treatment of hematological
disorders such as myelodysplastic syn-
drome and acute myeloid leukemia
(35,36). In recent years, stem cell therapy
has been used to improve postmyocardial
infarction, ventricular repair, and remod-
eling mechanisms (37). In this context,
stem cell therapy may be associated with
better functional recovery of the infarcted
ventricles in treated patients (38–40).
Recent studies reported the presence
of estrogen and testosterone receptors on
stem cells (41–43), suggesting that estro-
gen and testosterone may modify the
function of those cells (18,19,44,45)
(Figures 1 and 2). 17β-estradiol en-
hances the proliferation and migration
of endothelial progenitor cells (EPCs) to
the injured vessels, or ischemic myocar-
dial tissues, which, through the process of
homing, help in repair and regeneration
to compensate for the lost tissue. It also
has been postulated that vascular en-
dothelial growth factor (VEGF) might be
responsible for EPC migration in re-
sponse to 17β-estradiol (44). On the con-
trary, the role of androgens on stem cells
is controversial, but most studies sug-
gest that androgens have inhibitory ef-
fects on stem cell functions, and anti-
androgens could negate these effects (41).
Thus, modification of the function of stem
cells through estrogenic or anti-androgenic
stimulus may help formulate “super stem
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cells” with better therapeutic efficacy. To
achieve this goal, the role of sex hormones
on stem cell function must be elucidated.
It is the purpose of this review to summa-
rize the current knowledge of the effects
of estrogens and androgens on various
stem cell populations.
Embryonic Stem Cells
The expression of estrogen receptors
ER-α and ER-β in embryoid bodies takes
place as early as d 2, suggesting the in-
fluence of estrogen on the differentiation
and proliferation of human embryonic
stem cells (ESCs) and embryoid bodies
(43). The effects of estrogens on ESC
proliferation have been demonstrated
by Han et al. 17β-estradiol induces an in-
crease of ([3] H) thymidine incorporation
by murine ESCs and enhances DNA syn-
thesis, which is in turn inhibited by anti-
estrogen tamoxifen. Estrogens upregulate
the expression of ERα and ERβ protein
levels and increase mRNA expression
of the proto-oncogenes c-fos, c-jun, and
c-myc. In addition, 17β-estradiol acti-
vates the MAPK cascade as well as
cyclin-dependent kinases, with associ-
ated increases in cyclins D1 and E, which
are important intermediaries in cell cycle
progression (42).
Although it is known that estrogens en-
hance the proliferation of embryonic stem
cells, the role of androgens is not well un-
derstood. The presence of androgen re-
ceptors (AR) in ESCs has been detected as
early as 4.5 d in mice and 5 d in humans,
and it also was observed that the concen-
tration of AR increases during differentia-
tion of ESCs in a stage-dependent manner
(46). Testosterone or dihydrotestosterone
treatment is not associated with any sig-
nificant change in androgen receptor
mRNA expression level. But, in a contrast
that suggests a testosterone depletion ef-
fect, nilutamide, a nonsteroidal antiandro-
gen, causes proliferation of ESCs through
an increase of Akt protein expression and
decreased cell-cycle inhibitor p27 (Kip1)
expression (41). These findings suggest a
definite role of both sex steroids in the
differentiation and proliferation of embry-
onic stem cells.
Mesenchymal Stem Cells
MSCs are novel therapeutic agents for
organ protection, and estrogens may en-
hance the protective function of MSCs
by increasing or decreasing cytokine and
growth factor production in these cells
(47). Our previous study proved that
gender differences exist in activated MSC
function. In particular, lipopolysaccha-
ride- (LPS) and hypoxia-induced VEGF
production was significantly greater in
female MSCs compared with male MSCs.
Female MSCs express significantly less
pro-inflammatory cytokines, TNF-α and
IL-6, compared with male MSCs in re-
sponse to acute LPS and hypoxia, sug-
gesting their ability to limit inflamma-
tory reactions (18). In males, TNFR1
regulates VEGF, TNF, and IL-6 produc-
tion, whereas TNFR expression status
does not affect cytokine and growth
hormone production in females (19). We
also observed gender differences in stem
cell-mediated protection in a Langen-
dorff preparation. Rat hearts were sub-
jected to 25 min of warm global ischemia
followed by 40 min of reperfusion and
were assigned randomly to one of three
groups: (a) vehicle treated; (b) male MSC
treated; and (c) female MSC treated. Fe-
male MSC-treated hearts exhibited sig-
nificantly improved contractility and
compliance as compared with hearts
treated with male MSC or vehicle (48).
Regarding the role of estrogens in
osteogenic differentiation of MSCs,
there is evidence that 17β-estradiol sup-
ports growth and differentiation mostly
through the ERα receptor (49). This re-
ceptor bias may be attributed to in-
terindividual variability and gender
differences of osteoblast responses of
MSCs to estrogen manifested by ERα
polymorphism. In terms of male sex
hormone effects, testosterone decreases
the specific alkaline phosphatase activ-
ity in male MSCs but does not affect
calcium deposition in either sex (50).
Bone marrow MSCs, when exposed to
osteogenic differentiation medium sup-
plemented with 17β-estradiol, increase
the expression of bone morphogenetic
protein (BMP) and osteocalcin, and
significantly increase the deposition of
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Figure 1. Effects of estrogen on various stem cells and progenitor cells. ESC (embryonic
stem cell); EPC (endothelial progenitor cell); MSC (mesenchymal stem cell); HSC
(hematopoietic stem cell); CF (cardiac fibroblast); BMP (bone matrix protein); RUNX2/
CBFA1 (runt-related transcription factor 2/core-binding factor alpha).
calcium (51,52). 17β-estradiol also stim-
ulates the expression of osteogenic
genes for ALP, collagen I, and TGF-β1
by MSCs (12). These observations sug-
gest the bulk of the heavy lifting in
bone metabolism/physiology is han-
dled by the female sex steroids.
Clues to the molecular mechanisms
underlying the role of sex hormones in
MSC differentiation may be found in
the ERK pathway. Resveratrol, a phy-
toestrogen found in red wine, stimu-
lates the expression of osteoblastic
markers such as RUNX2/CBFA1, os-
terix, and osteocalcin in human bone
marrow mesenchymal stem cell cul-
tures. This effect is associated with a
rapid activation of ERK1 and ERK2,
and also can be inhibited by the ERK
inhibitor PD98059. Resveratrol en-
hances osteoblastic maturation and cal-
cium deposition into the extracellular
matrix (53) and its effects on osteoblas-
tic differentiation are mediated through
NO/cGMP pathway (54). Sex hormone
involvement in MSC function also in-
cludes leptin- and vitamin D-linked
increases in aromatase activity during
osteogenesis, leading to osteogenic
differentiation of MSCs (55) and signifi-
cant E2 linked increases in the lipid
stores of differentiated adipocytes (52).
Hematopoietic Stem Cells
There are gender differences in
hematopoietic progenitor cell concentra-
tions in cord blood samples collected
from infants. Specifically, male infants
had significantly higher median CD34+
cell concentrations than female infants
(31.8/μL compared with 30.2/μL, respec-
tively; P = 0.03). This relative increase is
reflected in adult males, who, when com-
pared with age-matched females, have an
increased number of colony-forming cells,
erythroblastic colonies, and granulocyte-
macrophage colonies in their peripheral
blood (56). This signifies that gender
may affect the hematopoietic potential
of cord blood transplants (57).
The effect of sex steroids on B lym-
phopoiesis is the subject of extensive,
continuing study. Sex steroids suppress
B lymphocyte production in murine bone
marrow. Pre B-lymphocytes produce the
heavy chain of IgM (μ chain) (58), under
the influence of the IgM constant region
gene (cμ) (59), which can act as a marker
of pre-B cells. V(D)J recombination con-
fers the ability of the immune system to
respond to a vast number of foreign anti-
gens, which occurs particularly in imma-
ture lymphocytes and is mediated by
the recombination activating gene prod-
ucts Rag1 and Rag2 (60,61). 17β-estradiol
treatment reduces cμ+ pre-B cells, as-
sociated with a decrease in Ig gene re-
arrangements and rag1 transcripts (62).
It also has been demonstrated that ERα
is predominantly responsible for mediat-
ing 17β-estradiol induced changes in 
B-cell precursors (63,64). These findings
suggest that 17β-estradiol exerts negative
influence on the production of B-lineage
cells by modifying the differentiation,
proliferation, and survival of early B-cell
precursors.
A novel system for expansion of
hematopoietic stem cells utilizes “selec-
tive amplifier genes” that encode fusion
proteins (granulocyte colony-stimulating
factor [G-CSF] mutant receptor and delta
G-CSF mutant receptor) between the
granulocyte colony-stimulating factor
receptor (G-CSF-R) and the hormone-
binding domain of estrogen receptor (ER).
ERs were replaced with a mutant recep-
tor (TmR), which specifically binds to
4-hydroxytamoxifen (Tm). Interleukin-3
(IL-3)-dependent Ba/F3 (mouse periph-
eral blood pro-B) cells and hematopoietic
progenitor cells transduced with the fu-
sion proteins showed IL-3-independent
growth in response to Tm, whereas, the
cells were insensitive to estrogen at con-
centrations up to10(–7) M to 10(–6) M.
Murine bone marrow cells transduced
with G-CSF-TmR and delta G-CSF-TmR
formed colonies in methyl-cellulose
medium in response to Tm, but no
colonies appeared with 10(–7) M estrogen
or without cytokines. These results sug-
gest that the influences of endogenous
estrogen can be ablated by using the
G-CSF-TmR/Tm or delta G-CSF-TmR/
Tm system to expand hematopoietic
stem cells with potential therapeutic ap-
plication (65).
Androgens exert an inhibitory effect
on B lymphopoiesis (66,67), but enhance
erythropoietic differentiation (68) and
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Figure 2. Effects of androgens on various stem cells and progenitor cells. ESC (embryonic
stem cell); EPC (endothelial progenitor cell); HSC (hematopoietic stem cell); NSC (neural
stem cell); OPC (osteogenic progenitor cell).
thrombocytopoiesis (69). Cultures of
human erythropoietic precursor cells col-
lected from children’s normal marrow
in the presence of erythropoietin demon-
strated a significant increase in the num-
ber of colony-forming units (CFU-E) and
burst-forming units (BFU-E) of derived
colonies in the presence of androgens
(10(–8) M or 10(–7) M). These colonies also
showed increased uroporphyrinogen I
synthase activity, indicating increased
heme synthesis (68). Androgens also can
rescue mature erythroid colony-forming
cells from apoptosis induced by serum
and growth factor deprivation (70), thus
increasing erythrocyte population. Inter-
estingly, castration of normal male mice
leads to splenic enlargement and expan-
sion of the B cell population, which is
mediated via androgen receptors present
in both immature B cells and marrow
stromal cells. These effects can be re-
versed with androgen replacement (66),
further elucidating the role of the male
hormone in lymphopoiesis.
Cardiac Fibroblasts
Gender may affect the healing of ische-
mic myocardium through changes in
the function of cardiac fibroblasts (CFs).
These progenitor cells play a significant
role in the remodeling of ischemic my-
ocardium, and the signal transduction
pathways controlling the proliferation of
CFs under hypoxia-induced stress reveal
significant gender differences. These
studies found females to be resistant to
hypoxia-induced inhibition of DNA syn-
thesis associated with decreased expres-
sion of NFκB and increased expres-
sions of p53 and bcl-2 in comparison to
males (71,72). Estrogens exert modula-
tory effects on cardiac fibroblast func-
tion. 17β-estradiol inhibits prolifera-
tion and collagen synthesis (3H-proline
incorporation) in male and female CFs
in a similar way, and facilitates benefi-
cial cardiac remodeling following is-
chemia. Consequently, hormone re-
placement therapy using 17β-estradiol
may exert protective effects on post
menopausal women against cardiovas-
cular events (73).
Cardiac fibroblasts express estrogen
receptor protein, and stimulation of CFs
with 17β-estradiol causes nuclear translo-
cation of these proteins, indicating one
effect of estrogen on gene regulation (74).
In cardiac fibroblasts, 17β-estradiol plays
an inhibitory role on renin-angiotensin
system-induced gene expression, signal
transduction, and ECM remodeling. An-
giotensin II increases fibroblast prolifera-
tion and synthesis of collagen types I
and III through the upregulation of ex-
pression of the angiotensin AT(1) recep-
tor gene and β1 integrins. 17β-estradiol
can prevent these increases in prolifera-
tion and AT(1) receptor mRNA levels
and can attenuate the collagen synthesis
in response to angiotensin II. 17β-estra-
diol inhibits AngII-stimulated expression
of β1 integrins significantly and attenu-
ates collagen gel contraction (75).
Estrogens can improve cardiac fibroblast-
mediated remodeling of ischemic myo-
cardium through both genomic and
nongenomic mechanisms. 17β-estradiol
exerts an inhibitory effect on the growth
of cardiac fibroblasts through both ERα
and ERβ (76). Underlying molecular
mechanisms include increased mitogen-
activated protein (MAP) kinase p42/44
activation and decreased p38 activation
(77). In addition, 17β-estradiol increases
the steady-state mRNA level of trans-
forming growth factor-β3 and fibronectin
in these cells (78). A recent study has
demonstrated that the selective estrogen
receptor agonists PPT (4,4’,4’’-[4-propyl-
([1]H)-pyrazole-1,3,5-triyl] tris-phenol) for
ER-α and DPN (2,3-bis[4-hydroxyphenyl]-
propionitrile) for ER-β, stimulate the
large-conductance Ca++-activated K+
(BK[Ca]) channels in cultured human
cardiac fibroblasts (HCFs). In whole-cell
configuration, depolarizing pulses
evoked large outward currents (Ik) with
an outward rectification, the amplitude
of which was increased in the presence
of DPN or PPT. Paxilline, a selective
blocker of BK(Ca) channels, could re-
verse the DPN- or PPT-induced ampli-
tude of Ik. However, no change in the tran-
scriptional level of the BK(Ca)-channel
α-subunit was observed by RT-PCR
analysis in chronic treatment with these
two compounds. These findings suggest
that estrogen induces a rapid stimulatory
effect on human cardiac fibroblasts via a
nongenomic mechanism through the ac-
tivation of BK(Ca)-channels (79). Build-
ing on this understanding of the molecu-
lar mechanisms in cardiac fibroblasts
may enable us to modify the functions of
these cells.
Endothelial Progenitor Cells
Blood contains endothelial progenitor
cells (EPC), which can differentiate into
endothelial cells and modulate healing
of injured vessels. In one study on a
healthy middle-aged population without
known cardiovascular risk factors, it has
been demonstrated that women exhib-
ited a distinctly higher EPC colony-
forming capacity (approximately 150%)
and greater migratory activity (40%)
compared with men (80). Moreover,
human women with a higher plasma
estrogen concentration showed a signifi-
cantly higher level of circulating EPCs.
Increase in the number of EPCs by 17β-
estradiol is mediated by decreased rate of
apoptosis through a caspase-8-dependent
pathway (81). The effects of estrogen on
EPCs are mediated via ERα receptor
(82). However, another similar study
failed to demonstrate significant gender-
specific differences in the frequency of
colony formation (83).
To explore sex hormone specificity in
EPCs, ERα KO mice were treated with
17β-estradiol, which failed to induce mi-
gration, tube formation, adhesion, and
estrogen-responsive element-dependent
gene transcription activities. In bone mar-
row transplantation models, endogenous
EPC migration and capillary density at
the border zone of ischemic myocardium
was reduced in 17β-estradiol treated ERα
KO mice. Using a murine ischemic heart
model, it also was shown that migration
of EPCs into the ischemic border zone
was impaired in ERα KO bone marrow
transplant mice. Downregulation of
VEGF also was noted in EPCs from
ERα KO mice both in vivo and in vitro
(44). It was postulated that 17β-estradiol
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mobilizes EPCs via endothelial nitric
oxide synthase–mediated activation of
matrix metalloproteinase-9 (84). Upregu-
lation of MMP-9 results in the release of
soluble Kit-ligand (sKitL), which facili-
tates the transfer of endothelial cells from
the quiescent to proliferative pool (85).
Disease models in animals also have
been employed to examine the effects of
sex hormones on progenitor cell func-
tionality. In spontaneously hypertensive
rats, the number of differentiated and
adherent EPCs derived from bone mar-
row was lower compared with age-
matched normotensive rats. Treatment
with 17β-estradiol significantly increases
the number of EPCs. EPCs derived from
hypertensive rats show low telomerase
activity and early senescence. Estrogen
treatment delays senescence and aug-
ments telomerase activity through PI3-K/
Akt pathway (86,87).
Regarding male sex hormone effects,
recent clinical studies suggest that an-
drogens increase the number of circulat-
ing EPCs through a possible effect on
bone marrow. It has been revealed that
hypogonadotrophic hypogonadal men
have low circulating EPCs that increase
significantly after androgen treatment
(88). A direct effect of testosterone also
was suggested by expression of andro-
gen receptor (AR) mRNA and protein
in human EPCs. Synthetic androgen,
methyltrienolone (R1881), causes AR
translocation in the nucleus, suggesting
its activation increases proliferation,
migration, and colony formation activ-
ity of these cells. Proliferation, migra-
tion, and colony formation activities of
the EPCs could be abolished by pre-
treatment with flutamide (89). A greater
understanding of these molecular mech-
anisms will yield insights into how gen-
der differences affect the healing process
in patients.
Preadipocytes
Regulation of lipid metabolism plays
a key role in atherosclerosis and ische-
mic cardiac diseases. Estrogens con-
trol the expression of lipogenic genes
such as leptin, perilipin, peroxisome
proliferation activator receptor-delta,
and lipoprotein lipase in adipocytes
and estrogen supplementation helps to
reduce adipose mass and adipocyte
size and prevents development of obe-
sity in postmenopausal state (90–92) by
both genomic and nongenomic mecha-
nisms (93). Genomic effects of estrogen
are limited to the regulation of leptin
and lipoprotein lipase expression
whereas nongenomic effects are medi-
ated via the s messenger systems,
namely cAMP cascade and the phos-
phoinositide cascade. Activation of the
cAMP cascade by estrogen is followed
by activation of hormone-sensitive li-
pase leading to lipolysis in adipose
tissues. Activation of protein kinase C
through the PI3K cascade, controls
the proliferation and differentiation
of preadipocytes (93). Human pre-
adipocytes (PAs) possess ERα protein
and express ERα gene, but do not ex-
press ERβ receptors, indicating that 
effect of estrogen on adipogenesis is
mediated through the ERα receptor
(52,94,95). The effects of estrogens on
ERα is site specific (95).
In humans, development of abdomi-
nal fat deposition is inversely propor-
tionate to blood testosterone levels (96).
Androgen receptors are found on
preadipocytes (97,98) and the effects
of testosterone on these cells also are
site-specific. Castration is associated
with increased proliferation and differen-
tiation of epididymal and perirenal
preadipocytes in male rats; whereas,
peripubertal testosterone supplementa-
tion reduces inguinal and retroperi-
toneal fat depots of ovariectomized
(OVX) rats. Testosterone decreases
adipocyte proliferation without affect-
ing adipocyte mean cell size or the size
distribution profiles (99). Androgens
act directly on fat cells by upregulating
α 2-AR expression (100). Androgens
also exert their modulatory effects on
the transcription factor C/EBP α, which
is a key regulator of the expression of
adipogenic genes (101), providing mo-
lecular context for gender-based effects
on adipocyte physiology.
Osteogenic Progenitors
Estrogen and testosterone play crucial
roles in bone metabolism. Even in males,
estrogen is critical for the pubertal
growth spurt characterized by skeletal
maturation, accrual of peak bone mass,
and the maintenance of bone mass in the
adult through its effects on remodeling
and bone turnover (102).
In OVX rats, estrogen deficiency
causes osteopenia and induces bone
turnover. Endosteal bone formation in
OVX rats is associated with an increased
proliferation of both osteoblast precursor
cells present in the marrow stroma and
along the endosteal bone surface. The os-
teoclast surface (percent of the bone tra-
becular surface covered with osteoclasts)
also increases in OVX rats following
ovariectomy, suggesting that bone for-
mation increases in correlation with
bone resorption. Estradiol supplementa-
tion reverses both the increase in resorp-
tion and formation indices (103).
Interestingly, 17β-estradiol, through
the ERα receptor, increases bone matrix
protein (BMP)-2, and BMP-4 expression.
It also attenuates the self renewal of
early osteoblast progenitors (having
limited self-renewal capacity) for both
osteoblasts and osteoclasts. Both these
effects slow down bone remodeling
(104,105). Through TGF β, estrogen
causes repression of T cell proliferation
and differentiation, and inhibits INFγ
production. This subsequently decreases
TNF production and thus reduces osteo-
clastic activity (106). Ovariectomy in-
creases IL-12 and IL-18 secretion by
macrophages which result in enhanced
T cell activation and TNF production
causing bone loss (107). IL-6 (108-110)
and IL-7 also have been attributed to in-
duced bone loss associated with estrogen
deficiency (111), not only through in-
creased osteoclastic activity but also by
reducing bone deposition through
downregulation of the osteoblast-specific
transcription factor, core-binding factor
α 1/Runx2 (112). In addition, 17β-estradiol
exerts its inhibitory effect on osteoclasts
through the regulation of VEGF produc-
tion; ovariectomized mice were associated
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with increased VEGF production and in-
creased osteoclastic activity (113).
Testosterone also has beneficial effects
on bone metabolism in adult males me-
diated by androgen receptors. Different
genomic and nongenomic pathways are
believed to be involved in mediating the
effects of testosterone on bone metabo-
lism. The nongenomic effects are medi-
ated via Akt activation (114) through
stimulation of src kinase (115,116). MAP
kinase signaling cascade also is activated
with testosterone treatment resulting in
increased expression of Raf-1 and ERK-2
(115). Insulin like growth factor-I (IGF-I),
and insulin like growth factor binding
proteins (IGFBP) also play a significant
part. Androgen decreases insulin like
growth factor binding protein IGFBP-4
which is inhibitory for osteoblasts, and
increases IGFBP-2 and IGFBP-3 mRNA
and protein levels, which have stimula-
tory effects on osteoblasts (117).
The genomic effect of testosterone is
mediated by the increased osteoprote-
gerin (OPG) expression. Osteoprotegerin
is a receptor activator of NF-κB ligand,
which inhibits the differentiation of the
osteoclast precursor into a mature osteo-
clast (118). However, the effect of testos-
terone on osteoprotegerin expression is
controversial. Some authors have demon-
strated that 5α-dihydrotestosterone
(DHT) reduces OPG in a dose-dependent
manner (119). In total, these observations
underscore the importance of understand-
ing the differential effects of sex hormones
on bone metabolism and physiology.
Neural Stem Cells
Estrogens modulate neurogenesis dur-
ing embryonic development. Estrogens
induce the neuronal phenotype in embry-
onic stem cell culture and enhance prolif-
eration of embryonic neural stem cells,
increasing the ratio of neurons to glial
cells (120,121). In combination with poly-
L-ornithine/fibronectin, estrogens also
have been shown to accelerate differenti-
ation and maturation of neurons (121).
Furthermore, estrogens also enhance dif-
ferentiation and survival of dopaminergic
neurons harvested from human neural
stem cells, suggesting a possible role of
estrogens in the transplantation of neural
stem cells as a therapeutic approach for
Parkinson’s disease (122). Like the previ-
ously discussed cell types, beneficial ef-
fects of estrogens on neurons are medi-
ated through both genomic and
nongenomic pathways (123,124).
Testosterone has a negative influence
on neural stem cell proliferation. Nan-
drolone (19-Nortestosterone) reduces cell
proliferation in neural stem cells stimu-
lated with epidermal growth factor,
which can be reversed by flutamide, a
receptor antagonist. Nandrolone also de-
creases the BrdU labeling of neural stem
cells in the dentate gyrus, indicating re-
duced cell proliferation in vivo (125).
These observations serve to emphasize
the differential role of gender specific
hormones on neural cell ontogeny.
CONCLUSION
Sexual dimorphism clearly influences the
function of various stem cell types through-
out the body. A better understanding of the
effects of estrogen and testosterone on these
cells will allow investigators and clinicians
to modulate the functions of these cells di-
rectly, with the ultimate goal of generating
more potent stem cell applications for the
treatment of human disease.
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